1
|
Godel M, Morena D, Ananthanarayanan P, Buondonno I, Ferrero G, Hattinger CM, Di Nicolantonio F, Serra M, Taulli R, Cordero F, Riganti C, Kopecka J. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. Int J Mol Sci 2020; 21:ijms21124500. [PMID: 32599901 PMCID: PMC7349977 DOI: 10.3390/ijms21124500] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 06/19/2020] [Accepted: 06/21/2020] [Indexed: 02/07/2023] Open
Abstract
Doxorubicin (Dox) is one of the most important first-line drugs used in osteosarcoma therapy. Multiple and not fully clarified mechanisms, however, determine resistance to Dox. With the aim of identifying new markers associated with Dox-resistance, we found a global up-regulation of small nucleolar RNAs (snoRNAs) in human Dox-resistant osteosarcoma cells. We investigated if and how snoRNAs are linked to resistance. After RT-PCR validation of snoRNAs up-regulated in osteosarcoma cells with different degrees of resistance to Dox, we overexpressed them in Dox-sensitive cells. We then evaluated Dox cytotoxicity and changes in genes relevant for osteosarcoma pathogenesis by PCR arrays. SNORD3A, SNORA13 and SNORA28 reduced Dox-cytotoxicity when over-expressed in Dox-sensitive cells. In these cells, GADD45A and MYC were up-regulated, TOP2A was down-regulated. The same profile was detected in cells with acquired resistance to Dox. GADD45A/MYC-silencing and TOP2A-over-expression counteracted the resistance to Dox induced by snoRNAs. We reported for the first time that snoRNAs induce resistance to Dox in human osteosarcoma, by modulating the expression of genes involved in DNA damaging sensing, DNA repair, ribosome biogenesis, and proliferation. Targeting snoRNAs or down-stream genes may open new treatment perspectives in chemoresistant osteosarcomas.
Collapse
Affiliation(s)
- Martina Godel
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
| | - Deborah Morena
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
| | - Preeta Ananthanarayanan
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
| | - Ilaria Buondonno
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
| | - Giulio Ferrero
- Department of Computer Science, University of Torino, 10149 Torino, Italy; (G.F.); (F.C.)
- Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Italy
| | - Claudia M. Hattinger
- Laboratory of Experimental Oncology, Pharmacogenomics and Pharmacogenetics Research Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (C.M.H.); (M.S.)
| | - Federica Di Nicolantonio
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
- Candiolo Cancer Institute, FPO–IRCCS, 10060 Candiolo, Italy
| | - Massimo Serra
- Laboratory of Experimental Oncology, Pharmacogenomics and Pharmacogenetics Research Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (C.M.H.); (M.S.)
| | - Riccardo Taulli
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
| | - Francesca Cordero
- Department of Computer Science, University of Torino, 10149 Torino, Italy; (G.F.); (F.C.)
| | - Chiara Riganti
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
- Correspondence: (C.R.); (J.K.); Tel.: +39-0116705857 (C.R.); +39-0116705849 (J.K.)
| | - Joanna Kopecka
- Department of Oncology, University of Torino, 1026 Torino, Italy; (M.G.); (D.M.); (P.A.); (I.B.); (F.D.N.); (R.T.)
- Correspondence: (C.R.); (J.K.); Tel.: +39-0116705857 (C.R.); +39-0116705849 (J.K.)
| |
Collapse
|
2
|
Dusinska M, Costa S, Collins A. Introduction to hCOMET special issue, 'Comet assay in vitro'. Mutat Res 2019; 845:403071. [PMID: 31561893 DOI: 10.1016/j.mrgentox.2019.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
| | - Solange Costa
- Department of Environmental Health, Portuguese National Institute of Health, Porto, Portugal
| | - Andrew Collins
- Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway
| |
Collapse
|